09 Jul 2021
Manual storage systems are projected to register 64% share in the biobanking market by 2027, given their low capital requisites. However, players in the biobanking market are increasingly striving to transform the landscape through the introduction of advanced software, which helps in reducing manual errors. Automated storage systems offer high precision and time-efficiency, which is likely to significantly increase their adoption in the foreseeable future. Automated storage systems are projected to register a CAGR of 7% during the forecast period (2020-2027).
A recent study published by Fact.MR examines the growth potential of the biobanking market, and projects CAGR to be above average during the forecast period.
A senior research analyst at Fact.MR opines,
“Though the application of biospecimen for the development of therapeutics is growing, there will be a notable spurt in the adoption rate of bio-samples for clinical diagnosis to understand cell structure.”
Product innovation is a key strategy adopted by players in the biobanking market. As biobanking of biospecimen requires freezing temperature for storage, leading players are, in turn, making a shift towards offering products with the least possible carbon footprints. Thermo Fisher Scientific, Inc. is an ideal company exhibiting this strategic move. In 2017, the company announced that it had received the ENERGY STAR certification for its temperature freezers from the U.S. Environmental Protection Agency to reduce energy consumption, while ensuring the protection of biospecimen.
Players operating in other tiers seek expansion in the fragmented biobanking market through collaborations, acquisitions, and partnerships, to achieve better exposure of their products.
Fact.MR, in its new offering, brings to the fore an unbiased analysis of the global biobanking market, presenting historical demand data (2017-2019), and forecast statistics for the period of 2020-2027. The study divulges compelling insights on the biobanking market on the basis of product (equipment, consumables, software & services), biospecimen (blood products, human tissues, cell lines, nucleic acids, and others), application (therapeutics, clinical diagnostics, drug discovery & development, and others), and storage (manual and automated), across five major regions.
The healthcare team at Fact.MR assists clients with unique business intelligence needs on a global level. With a repertoire of over 1,000 reports and 1 million+ data points, the team has analysed the healthcare industry to a micro-level across 50+ countries for over a decade. The team provides end-to-end research and consulting services to help keep clients at the top of the game. Reach out to us to know how we can help.
Biobanking Market
Free SampleAbout Fact.MR
Fact.MR is a market research and consulting agency with deep expertise in emerging market intelligence. We are known for our syndicated research, custom research, and consulting solutions.